Several multi-gene assays have been developed to predict the risk of recurrence in patients with early-stage

estrogen receptor (ER) positive breast cancer. Among them

Oncotype DX 21-gene assay is widely applied among node-negative patients because of its unique prediction of therapeutic benefit. Although many retrospective studies have proved its prognostic and predictive value in node-positive population

evidence from large prospective clinical trials remains insufficient. When combined with clinicopathological variables

the assay has been shown to impact adjuvant treatment decision making in a cost-effective manner. This article reviewed the available clinical evidence for the prognostic and predictive value

unique advantages

the effect on treatment decision making

cost-effectiveness and contradictories of 21-gene assay in early-stage luminal breast cancer patients.